# FGD1

## Overview
The FGD1 gene encodes the FYVE, RhoGEF, and PH domain-containing protein 1, which is a guanine nucleotide exchange factor (GEF) that plays a pivotal role in cellular signaling pathways. This protein is primarily involved in the activation of the Rho GTPase Cdc42, a key regulator of the actin cytoskeleton, influencing cell shape, motility, and various cellular processes such as vesicular transport and cell cycle progression (Zhu2022FGD1; Hou2003Fgd1). The FGD1 protein is characterized by its modular structure, which includes domains such as a proline-rich SH3-binding domain, a RhoGEF domain, two pleckstrin homology (PH) domains, and a cysteine-rich zinc finger domain, facilitating its interaction with other proteins and cellular components (Völter2014AarskogScott). Mutations in the FGD1 gene are linked to Aarskog-Scott syndrome, an X-linked recessive disorder marked by developmental anomalies, underscoring the gene's clinical significance (Ge2017Novel; Orrico2010Aarskog–Scott).

## Structure
The FGD1 protein is composed of 961 amino acids and includes several distinct domains that contribute to its function and structure. These domains include a proline-rich SH3-binding domain, a RhoGEF domain, two pleckstrin homology (PH) domains, and a cysteine-rich zinc finger domain (Völter2014AarskogScott). The RhoGEF domain is crucial for activating the Rho GTPase Cdc42, which is important for actin cytoskeleton organization (Hou2003Fgd1). The PH domains are involved in binding inositol phospholipids, which play a role in signal transduction and cellular localization (Orrico2000A).

The FGD1 protein also contains a FYVE domain, which is involved in phosphoinositide binding, suggesting a role in membrane association (Hou2003Fgd1). The protein's structure is modular, facilitating interactions with other proteins and cellular components (Völter2014AarskogScott). A naturally occurring splice variant of FGD1, which lacks a portion of the DH domain, has been identified and may act as a dominant-inhibitory mutant (Whitehead1998CDC42). The presence of these domains indicates a complex tertiary structure with potential for multiple interactions and functions, although specific details on the primary, secondary, or quaternary structures are not provided in the context.

## Function
The FGD1 gene encodes a guanine nucleotide exchange factor (GEF) that specifically activates the Rho GTPase Cdc42, a critical regulator of the actin cytoskeleton and cell shape. In healthy human cells, FGD1 facilitates the exchange of GDP for GTP on Cdc42, which is essential for various cellular processes, including actin polymerization, vesicular transport, cell cycle progression, and cell polarity (Zhu2022FGD1; Hou2003Fgd1). FGD1 interacts with proteins such as cortactin and mAbp1, which are involved in actin cytoskeletal organization, to regulate the activation of the Arp2/3 complex, leading to actin filament branching and filopodia formation (Hou2003Fgd1).

FGD1 is primarily active in the cytoplasm, particularly in the subcortical actin cytoskeleton, where it influences cytoskeletal organization, cell polarity, and vesicular transport. This activity is crucial for maintaining cell shape and function, especially in osteoblasts, where FGD1 plays a significant role in bone development and differentiation (Hou2003Fgd1; Zou2011MLK3). The protein's function in healthy cells involves promoting the activity of Rho family GTPases, particularly Cdc42, which is implicated in various signaling pathways (Zou2011MLK3).

## Clinical Significance
Mutations in the FGD1 gene are primarily associated with Aarskog-Scott syndrome (AAS), also known as faciogenital dysplasia. This X-linked recessive disorder is characterized by a range of developmental anomalies, including short stature, facial dysmorphisms, skeletal deformities, and genitourinary malformations (Ge2017Novel; Orrico2010Aarskog–Scott). The FGD1 gene encodes a protein that functions as a guanine nucleotide exchange factor, specifically catalyzing the GDP-GTP exchange of the Rho GTPase Cdc42, which is crucial for cell growth regulation and cytoskeletal organization (German1994Isolation; Orrico2010Aarskog–Scott).

Clinical manifestations of AAS can vary widely, even among individuals with the same mutation, and include features such as hypertelorism, brachydactyly, shawl scrotum, and joint hyperextensibility (Orrico2010Aarskog–Scott; Li2024FGD1related). Neuropsychiatric disorders, including attention-deficit/hyperactivity disorder (ADHD), have also been observed in some patients, highlighting the variable clinical expression associated with FGD1 mutations (Orrico2005Attention‐deficithyperactivity). While severe mental retardation is not typically associated with FGD1 mutations, some individuals may exhibit neurobehavioral features within the ADHD spectrum (Orrico2010Aarskog–Scott). The lack of a clear genotype-phenotype correlation complicates diagnosis and underscores the importance of genetic testing in identifying FGD1-related conditions (Orrico2014Clinical).

## Interactions
The FGD1 protein, encoded by the FGD1 gene, is known for its interactions with cortactin and mouse actin-binding protein 1 (mAbp1), both of which are actin-binding proteins. These interactions are mediated through the Src Homology 3 Binding Domain (SH3-BD) of FGD1, which binds to the SH3 domains of cortactin and mAbp1. This binding is crucial for modulating cell shape and regulating the actin cytoskeleton (Hou2003Fgd1).

The interactions between FGD1 and these proteins have been confirmed through various methods, including yeast two-hybrid studies, biochemical assays, and immunoprecipitation studies. These studies demonstrate that FGD1 colocalizes with cortactin and mAbp1 in lamellipodia and membrane ruffles, indicating its dynamic subcellular targeting (Hou2003Fgd1).

FGD1's interaction with cortactin is particularly important for its proper localization and function in modulating cell shape and motility. Truncated cortactin proteins, which lack actin-binding domains, can redirect FGD1 from the cell cortex to the cytoplasm, leading to altered cell motility and actin cytoskeleton organization (Hou2003Fgd1). These interactions suggest that FGD1 plays a significant role in the regulation of the actin cytoskeleton and cell morphology.


## References


[1. (Orrico2010Aarskog–Scott) A. Orrico, L. Galli, L. Faivre, J. Clayton‐Smith, S.M. Azzarello‐Burri, J.M. Hertz, S. Jacquemont, R. Taurisano, I. Arroyo Carrera, E. Tarantino, K. Devriendt, D. Melis, T. Thelle, U. Meinhardt, and V. Sorrentino. Aarskog–scott syndrome: clinical update and report of nine novel mutations of the fgd1 gene. American Journal of Medical Genetics Part A, 152A(2):313–318, January 2010. URL: http://dx.doi.org/10.1002/ajmg.a.33199, doi:10.1002/ajmg.a.33199. This article has 43 citations.](https://doi.org/10.1002/ajmg.a.33199)

[2. (Whitehead1998CDC42) Ian P. Whitehead, Karon Abe, Jerome L. Gorski, and Channing J. Der. Cdc42 and fgd1 cause distinct signaling and transforming activities. Molecular and Cellular Biology, 18(8):4689–4697, August 1998. URL: http://dx.doi.org/10.1128/mcb.18.8.4689, doi:10.1128/mcb.18.8.4689. This article has 50 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.18.8.4689)

[3. (Orrico2014Clinical) Alfredo Orrico, Lucia Galli, Jill Clayton-Smith, and Jean-Pierre Fryns. Clinical utility gene card for: aarskog–scott syndrome (faciogenital dysplasia) – update 2015. European Journal of Human Genetics, 23(4):558–558, September 2014. URL: http://dx.doi.org/10.1038/ejhg.2014.178, doi:10.1038/ejhg.2014.178. This article has 12 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/ejhg.2014.178)

[4. (Li2024FGD1related) Sujuan Li, Anran Tian, Yu Wen, Wei Gu, Wei Li, Xiaohong Qiao, Cai Zhang, and Xiaoping Luo. Fgd1-related aarskog–scott syndrome: identification of four novel variations and a literature review of clinical and molecular aspects. European Journal of Pediatrics, 183(5):2257–2272, February 2024. URL: http://dx.doi.org/10.1007/s00431-024-05484-9, doi:10.1007/s00431-024-05484-9. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00431-024-05484-9)

[5. (Orrico2005Attention‐deficithyperactivity) Alfredo Orrico, Lucia Galli, Sabrina Buoni, Giuseppe Hayek, Anna Luchetti, Stefania Lorenzini, Michele Zappella, Maria Grazia Pomponi, and Vincenzo Sorrentino. Attention‐deficit/hyperactivity disorder (adhd) and variable clinical expression of aarskog–scott syndrome due to a novel fgd1 gene mutation (r408q). American Journal of Medical Genetics Part A, 135A(1):99–102, April 2005. URL: http://dx.doi.org/10.1002/ajmg.a.30700, doi:10.1002/ajmg.a.30700. This article has 28 citations.](https://doi.org/10.1002/ajmg.a.30700)

[6. (German1994Isolation) N. German Pasteris, Amy Cadle, Lindsay J. Logie, Mary E.M. Porteous, Charles E. Schwartz, Roger E. Stevenson, Thomas W. Glover, R. Sid Wilroy, and Jerome L. Gorski. Isolation and characterization of the faciogenital dysplasia (aarskog-scott syndrome) gene: a putative rhorac guanine nucleotide exchange factor. Cell, 79(4):669–678, November 1994. URL: http://dx.doi.org/10.1016/0092-8674(94)90552-5, doi:10.1016/0092-8674(94)90552-5. This article has 241 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/0092-8674(94)90552-5)

[7. (Orrico2000A) Alfredo Orrico, Lucia Galli, Michela Falciani, Martina Bracci, Maria Luigia Cavaliere, Maria Michela Rinaldi, Andrea Musacchio, and Vincenzo Sorrentino. A mutation in the pleckstrin homology (ph) domain of the fgd1 gene in an italian family with faciogenital dysplasia (aarskog–scott syndrome). FEBS Letters, 478(3):216–220, July 2000. URL: http://dx.doi.org/10.1016/S0014-5793(00)01857-3, doi:10.1016/s0014-5793(00)01857-3. This article has 53 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/S0014-5793(00)01857-3)

[8. (Hou2003Fgd1) P. Hou. Fgd1, the cdc42 gef responsible for faciogenital dysplasia, directly interacts with cortactin and mabp1 to modulate cell shape. Human Molecular Genetics, 12(16):1981–1993, July 2003. URL: http://dx.doi.org/10.1093/hmg/ddg209, doi:10.1093/hmg/ddg209. This article has 72 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddg209)

[9. (Zou2011MLK3) Weiguo Zou, Matthew B. Greenblatt, Jae-Hyuck Shim, Shashi Kant, Bo Zhai, Sutada Lotinun, Nicholas Brady, Dorothy Zhang Hu, Steven P. Gygi, Roland Baron, Roger J. Davis, Dallas Jones, and Laurie H. Glimcher. Mlk3 regulates bone development downstream of the faciogenital dysplasia protein fgd1 in mice. Journal of Clinical Investigation, 121(11):4383–4392, November 2011. URL: http://dx.doi.org/10.1172/jci59041, doi:10.1172/jci59041. This article has 53 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci59041)

[10. (Völter2014AarskogScott) Christiane Völter, Ramón Martínez, Rudolf Hagen, and Wolfram Kress. Aarskog-scott syndrome: a novel mutation in the fgd1 gene associated with severe craniofacial dysplasia. European Journal of Pediatrics, 173(10):1373–1376, April 2014. URL: http://dx.doi.org/10.1007/s00431-014-2317-3, doi:10.1007/s00431-014-2317-3. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00431-014-2317-3)

[11. (Zhu2022FGD1) Yilin Zhu, Qingqing Chen, Haiyan Lin, Huifei Lu, Yangbin Qu, Qingfeng Yan, and Chunlin Wang. Fgd1 variant associated with aarskog–scott syndrome. Frontiers in Pediatrics, July 2022. URL: http://dx.doi.org/10.3389/fped.2022.888923, doi:10.3389/fped.2022.888923. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fped.2022.888923)

[12. (Ge2017Novel) Yihua Ge, Niu Li, Zhigang Wang, Jian Wang, and Haiqing Cai. Novel variant in the fgd1 gene causing aarskog-scott syndrome. Experimental and Therapeutic Medicine, 13(6):2623–2628, April 2017. URL: http://dx.doi.org/10.3892/etm.2017.4301, doi:10.3892/etm.2017.4301. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/etm.2017.4301)